Results 221 to 230 of about 1,071,501 (260)

Performance of the Cobas® HBV RNA Automated Investigational Assay for the Detection and Quantification of Circulating HBV RNA in Chronic HBV Patients

open access: yesJournal of Clinical Virology, 2022
Abstract Background The amount of HBV RNA in peripheral blood may reflect HBV covalently closed circular DNA (cccDNA) transcriptional activity within infected hepatocytes. Quantification of circulating HBV RNA (cirB-RNA) is thus a promising biomarker for monitoring antiviral treatment.
Fabien Zoulim   +2 more
exaly   +4 more sources

Natural History of Serum HBV-RNA in Chronic HBV Infection

Journal of Viral Hepatitis, 2018
SummaryVirus‐like particles encapsulating HBV‐RNA represent a serum biomarker for assessing viral replication activity in clinical practice. However, baseline levels of serum HBV‐RNA and their associations with viral replicative intermediates and liver disease in phases of chronic hepatitis B remain unknown.
Jiming Zhang, Xuan-Yi Wang, Jing Wang
exaly   +3 more sources

Effects of on‐treatment ALT flares on serum HBsAg and HBV RNA in patients with chronic HBV infection

Journal of Viral Hepatitis, 2021
AbstractAs pegylated interferon alpha (PEG‐IFN‐α) is increasingly used in combination regimens of novel drugs, we aimed to characterize ALT flares and their relationship with serum HBsAg and HBV RNA kinetics in a large combined cohort of chronic hepatitis B (CHB) patients on PEG‐IFN‐α‐based therapy.
Hannah S. J. Choi   +9 more
openaire   +2 more sources

Circulating HBV RNA: From biology to clinical applications

Hepatology, 2022
Abstract Chronic HBV infection can hardly be cured due to the persistence of an intrahepatic pool of viral covalently closed circular DNA (cccDNA) transcription template, which is refractory to current antivirals.
Rui Deng   +4 more
openaire   +2 more sources

Sequence characterization of extracellular HBV RNA in patient plasma

Journal of Viral Hepatitis, 2022
AbstractAntiviral nucleos(t)ide analogue therapies inhibit HBV replication and suppress the HBV DNA levels in patients with chronic HBV infection. Since HBV RNAs are expressed from cccDNA or HBV integrated sequences, independently of viral genome replication, levels of HBV RNAs in plasma may remain high following treatment with nucleos(t)ide analogue ...
Chang, Silvia   +6 more
openaire   +3 more sources

Baicalin benefits the anti-HBV therapy via inhibiting HBV viral RNAs

Toxicology and Applied Pharmacology, 2017
Although current antiviral treatments (nucleoside analogs, NAs) for chronic hepatitis B virus (HBV) infection are effective in suppressing HBV-DNA replication, their clinical outcomes can be compromised by the increasing drug resistance and the inefficiency in promoting HBsAg/HBeAg seroconversion.In this study, we will explore possible effects and ...
Hai Huang   +4 more
openaire   +2 more sources

A novel, small anti-HBV compound reduces HBsAg and HBV-DNA by destabilizing HBV-RNA

Journal of Gastroenterology
Currently, standard treatments for chronic hepatitis B such as nucleos(t)ide analogs (NAs), effectively reduce hepatitis B virus (HBV) loads but rarely result in a functional cure (defined as sustained HBsAg loss). We report the discovery of a novel, 4-pyridone compound, SAG-524, a potent and orally bioavailable small molecule inhibitor of HBV ...
Takehisa Watanabe   +6 more
openaire   +2 more sources

[Clinical research progress of HBV RNA].

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2021
Hepatitis B virus RNA plays an important role in the process of hepatitis B virus replication, especially pregenomic RNA (pgRNA), which serves as a template for the viral capsids, so its particularity is increasing day by day. This article analyzes the recent clinical studies, and further discusses the guiding significance of HBV RNA as a new clinical ...
Y F, Xu, X Z, Lei
openaire   +1 more source

Home - About - Disclaimer - Privacy